Who Viking Therapeutics buys from and sells to
Clinical-stage biotech developing VK2735, an injectable and oral GLP-1/GIP obesity drug; no product revenue.
Part of GLP-1 and Specialty Pharmaceuticals spending
Buys from 1
- CordenPharmaVK2735 API, autoinjectors and tablets under a multi-year deal
Sells to 0
None recorded
Where the chain could break
- Sole commercial manufacturing deal is with CordenPharma ($150m prepayments)
- Phase 3 VANQUISH readouts decide whether there is a product at all
Competes with
- Eli LillyLLYtirzepatide, the incumbent dual-agonist it must beat
- Novo NordiskNVOsemaglutide injections and the Wegovy pill
- AmgenAMGNMariTide, another late-stage obesity injectable
- PfizerPFEMetsera's long-acting obesity candidates
Mapped by hand from filings and company reporting, as of October 2026. It shows the relationships that matter most, not every contract: most are never disclosed, and agreements change.